Objective: This study evaluates the prognostic significance of [18F]-fluoro-2-deoxyglucose positron emission tomography/computed tomography findings according to histological subtypes in patients with completely resected non-small cell lung cancer. Methods: We examined 176 consecutive patients who had undergone preoperative [18F]-fluoro-2-deoxyglucose-positron emission tomography/computed tomography imaging and curative surgical resection for adenocarcinoma (n ¼ 132) or squamous cell carcinoma (n ¼ 44). Maximum standardized uptake values for the primary lesions in all patients were calculated as the [18F]-fluoro-2-deoxyglucose uptake and the surgical results were analyzed.
INTRODUCTION
Positron emission tomography with [18F]-fluoro-2-deoxyglucose (FDG-PET) is a useful diagnostic tool for several malignancies that has proven superior to computed tomography (CT) for diagnosing lung cancer (1) . In addition, FDG-PET imaging is widely used to determine the tumor, node, metastasis (TNM) stage in patients with non-small cell lung cancer (NSCLC), thus altering the stage designation and management in 20 -40% of patients (2 -5) . Some recent reports indicate that the maximum standardized uptake value (SUVmax) determined by FDG-PET is a significant marker of the malignant grade of NSCLC (6) , especially in small adenocarcinoma (7, 8) . However, the correlation between SUV and tumor malignancy in squamous cell carcinoma is not understood in detail.
Therefore, we assessed the prognostic value of FDG-PET in patients with NSCLC according to histological subtypes. Because of the low frequencies of large cell carcinoma, adenosquamous carcinoma and other subtypes, we focused our investigation on adenocarcinoma and squamous cell carcinoma, which are the two major histological subtypes of NSCLC to be analyzed.
PATIENTS AND METHODS

PATIENTS
We obtained appropriate approval for the study from the Institutional Review Board of Hiroshima University (No. eki-256), which waived the requirement for informed consent from the individual patients for this retrospective review. We reviewed the medical records of 176 consecutive patients who met the inclusion criteria between April 2007 and December 2009, which comprised preoperative staging by PET/CT, surgery with curative intent without neoadjuvant chemotherapy or radiotherapy and a definitive histopathological diagnosis of lung adenocarcinoma or squamous cell carcinoma. Surgery with curative intent was considered complete resection with no residual carcinoma (R0 resection) and patients with incompletely resected tumors (R1 or R2 resection) were excluded from the study. Tumors ,1 cm were also excluded from this study as imaging such lung cancers using PET scanners is generally difficult. All patients were staged according to the seventh edition of the TNM classification of malignant tumors (9) . The following information was abstracted from the patients' charts: age at surgery, gender, SUVmax on FDG-PET/CT images, ratio (%) of ground-glass opacity (GGO), tumor diameter, lymph node status, staging, lymphatic invasion, vascular invasion, type of surgical procedure and ratio (%) of bronchioloalveolar carcinoma (BAC) component in adenocarcinoma.
HIGH-RESOLUTION CT
Chest images were obtained using 16-row multidetector CT independently of subsequent FDG-PET/CT examinations. High-resolution images of the tumors were acquired using the following parameters: 120 kVp, 200 mA, 1 -2 mm section thickness, 512 Â 512 pixel resolution, 0.5-to 1-s scanning time, a high spatial reconstruction algorithm with a 20 cm field of view (FOV) as well as mediastinal (level, 40 HU; width, 400 HU) and lung (level, 2600 HU; width, 1600 HU) window settings. GGO was defined as a misty increase in lung attenuation without obscuring underlying vascular markings, and we defined the GGO ratio (%) as [1 2 (maximum dimension of consolidation of lung windows/maximum dimension of tumor of lung windows)] Â 100.
FDG-PET/CT
The patients fasted for at least 4 h before being intravenously injected with 3.7 MBq/kg of FDG, and then they rested for 1 h before being scanned. Blood glucose was measured before tracer injection to ensure a level of ,150 mg/dl. Patients with blood glucose values of !150 mg/dl during PET/CT image acquisition were excluded. All patients were assessed using the integrated PET/CT scanner, Discovery ST16 (GE Healthcare). An unenhanced CT image of a 2 -4 mm thick section that matched the PET images was obtained from the head to the pelvic floor of each patient using a standard protocol. Immediately after CT, PET covered the identical axial FOV with 2 -4 min per table position depending on the condition of the patient and the scanner performance. Both PET and CT studies proceeded with normal tidal breathing. All PET images were reconstructed using an iterative algorithm with CT-derived attenuation correction using Fourier re-binning followed by ordered-subset expectation maximization (iteration number 5, subset number 16). SUVmax was established by drawing regions of interest around the primary tumor on attenuationcorrected FDG-PET images and calculated using the software within the PET/CT scanner based on the following formula: SUVmax ¼ [C(mCi/ml)/ID(mCi)]/w, where C is defined as activity at a pixel within the tissue identified by regions of interest and ID as the injected dose/kg of body weight (w). We adopted SUVmax in the present analysis because it is less variable than mean SUV in terms of measurements (10).
FOLLOW-UP EVALUATION
All patients who underwent lung resection were followed up from the day of surgery. Postoperative follow-up procedures, including a physical examination and chest roentgenogram every 3 months and a chest CT examination every 6 months, were performed for the first 2 years. Afterward, a physical examination and chest roentgenogram were performed every 6 months and a chest CT examination was performed every year. Recurrence was defined as any unequivocal occurrence of new cancer foci in a disease-free patient. The site of the first cancer recurrence and the interval between the surgery and cancer recurrence were determined. Locoregional recurrence was defined if it occurred within the same lobe, mediastinal lymph nodes or hilum. All other types of recurrence were categorized as distant recurrences. The duration of disease-free survival (DFS) was calculated as the interval between the surgery date and date of the first confirmation of Jpn J Clin Oncol 2011;41 (7) 891 cancer recurrence, death without evidence of recurrence or the last clinical contact attesting to a disease-free status.
STATISTICAL ANALYSIS
Data are presented as numbers (%) or the median unless otherwise stated. Frequencies were compared using the x 2 test for categorical variables, and Fischer's exact test was applied to small samples. Mann -Whitney U tests were performed when comparing continuous variables. Receiver operating characteristic (ROC) curves of the SUVmax for the prediction of recurrence were generated to determine the cutoff value that yielded optimal sensitivity and specificity. The patient population was subdivided based upon the cutoff value of SUVmax derived from ROC curves, and the duration of DFS was analyzed using the Kaplan -Meier method. Differences in DFS were assessed using the log-rank test. To assess the potential independent effects of SUVmax on DFS, we performed multivariate analyses using the Cox proportional hazards model with variables with a P value of ,0.05 in the univariate analyses, and P , 0.05 was considered to be statistically significant. Data were statistically analyzed using SPSS software (version 10.5, SPSS Inc., Chicago, IL, USA). Values are shown as median (range) or ratios (%). ADC, adenocarcinoma; SCC, squamous cell carcinoma; SUVmax, maximum standardized uptake value; GGO, ground glass opacity.
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SUVmax on PET for ADC and SCC of the lung Fig. 1A and B) , whereas the GGO ratio was lower for squamous cell carcinoma (median GGO ratio ¼ 0.0%) than for adenocarcinoma (median GGO ratio ¼ 16.0). Vascular invasion was more frequent for squamous cell carcinoma (46.3%) than for adenocarcinoma (26.0%). Age, tumor size, nodal status, pathological stage, lymphatic invasion, surgical procedure and tumor recurrence did not significantly differ between the two types of tumors.
RESULTS
We used ROC curve analyses to evaluate whether preoperative SUVmax on PET/CT predicted high-risk groups of recurrence. The ROC curves identified an optimal SUVmax cutoff value of 3.7 for predicting the recurrence of adenocarcinoma [n ¼ 132, area under the curve (AUC), 0.79; sensitivity, 88.0%; specificity, 67.3%], but not for squamous cell carcinoma (n ¼ 44; AUC, 0.63; Fig. 2A and B) . Therefore, the patient population was subdivided based upon the optimal SUVmax cutoff value of 3.7 in adenocarcinoma and the median SUVmax of 6.95 in squamous cell carcinoma.
At a cutoff value of 3.7, a high SUVmax significantly correlated with a low GGO ratio, large tumor, lymph node metastasis, lymphatic invasion, vascular invasion and recurrence in adenocarcinoma, but only with large tumors of squamous cell carcinoma at a cutoff value of 6.95 (Table 2) . Figure 3A shows a significant difference in DFS between patients whose adenocarcinoma had SUVmax 3.7 (2-year DFS rate, 93.9%) and .3.7 (2-year DFS rate, 52.4%; P , 0.0001). Even in Stage I adenocarcinoma, the 2-year DFS significantly differed between patients with SUVmax 3.7 and .3.7 (100 vs. 57.2%; P , 0.0001; Fig. 3B ). However, DFS did not significantly differ between patients whose squamous cell carcinoma had SUVmax of either 6.95 (2-year DFS rate, 70.2%) or .6.95 (2-year DFS rate, 59.3%; P ¼ 0.83; Fig. 3C ).
Univariate analysis of the DFS of 132 patients with adenocarcinoma included the variables of age, sex, SUVmax, tumor size, nodal status, lymphatic invasion, vascular invasion, BAC ratio and serum carcinoembryonic antigen level (Table 3 ). Higher SUVmax, larger tumors, positive lymph node metastasis, positive lymphatic invasion and lower BAC ratio were associated with a short DFS. Moreover, multivariate analysis that included SUVmax, tumor size, nodal status, lymphatic invasion and BAC ratio showed that SUVmax (hazard ratio 6.85; 95% CI: 1.65 -28.5; P ¼ 0.008) and lymph node metastasis (hazard ratio 4.99; 95% CI: 1.96 -12.7; P ¼ 0.001) were independent prognostic factors for DFS (Table 3) .
DISCUSSION
The significance of FDG-PET as a prognostic factor for each subtype of NSCLC is not understood in detail, although most publications that recognized correlations between SUV and stage, survival or recurrence grouped their study patients together regardless of the histological NSCLC subtype (6,11 -16) . We limited the present investigation to adenocarcinoma and squamous cell carcinoma, which are the two major histological subtypes of NSCLC.
The SUVmax was significantly higher for squamous cell carcinoma than for adenocarcinoma in the present Jpn J Clin Oncol 2011;41 (7) 893 study. A high SUVmax correlated with a low GGO ratio, large tumor, lymph node metastasis, positive lymphatic invasion and positive vascular invasion in patients with adenocarcinoma, but only with large tumors in patients with squamous cell carcinoma. Generally, FDG uptake is dependent on the tumor size (12 -14) and thus a relationship between SUVmax and tumor size in this study is inevitable for both subtypes. DFS was significantly worse in patients with a high, than with a low SUVmax at the cutoff value determined from the ROC curve for predicting adenocarcinoma recurrence. On the other hand, the SUVmax did not correlate with squamous cell carcinoma recurrence since the ROC curve for predicting recurrence could not identify an optimal cutoff value for SUVmax for this histological subtype. These results indicated that a high SUVmax is associated with malignancy and a worse prognosis for adenocarcinoma, but less so for squamous cell carcinoma. We found that SUVmax, tumor size, nodal status, lymphatic invasion and BAC ratio were significant prognostic factors for DFS in univariate analyses of patients with adenocarcinoma. Multivariate analysis revealed that the SUVmax and nodal status remained significant prognostic factors for DFS, indicating that SUVmax as well as nodal status is an important prognostic determinant, which is generally the most powerful prognostic factor for NSCLC. Despite the short follow-up of the present study, SUVmax was considered an independent prognostic factor in adenocarcinoma. Even when the study participants were limited to those with Stage I adenocarcinoma, high SUVmax was a poor prognostic factor for DFS. In contrast, the SUVmax 
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SUVmax on PET for ADC and SCC of the lung was irrelevant to the recurrence and prognosis of squamous cell carcinoma, thus confirming that discrimination of histological subtypes is very important for assessments of FDG-PET/CT findings. Altered glucose metabolism might explain the differences in the roles of SUVmax between adenocarcinoma and squamous cell carcinoma. Some studies have shown that tumor FDG uptake correlates with overexpression of the glucose transporter (GLUT)-1 in lung cancer (17, 18) . Ito et al. (19) reported that GLUT-1 is expressed in 100% of squamous cell carcinomas but only in 58% of adenocarcinomas. The discrepancy in GLUT-1 expression could explain the higher SUVmax for squamous cell carcinoma compared with adenocarcinoma. Other studies have demonstrated that GLUT-1 expression is associated with aggressive biological behavior and significantly poorer prognostic indicators in adenocarcinoma, but not in squamous cell carcinoma (20) . GLUT-1 expression by the primary tumor could explain the different significance of SUVmax as a prognostic factor between adenocarcinoma and squamous cell carcinoma.
The limitations of the study comprise the relatively small number of patients with squamous cell carcinoma and the short follow-up, which nevertheless allowed a clear conclusion using DFS and the obvious outcomes of patient survival. Further confirmation in a large cohort is required. Jpn J Clin Oncol 2011;41(7) 895
